Skye Bioscience, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting beneficial ownership of 3.60% of Skye Bioscience, Inc.'s common stock.
NASDAQ
Schonfeld Strategic Advisors LLC has reported a 5.22% beneficial ownership stake in Skye Bioscience, Inc., holding 1,617,697 shares of common stock.
NASDAQ
Sphera Funds Management Ltd. and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.77% in Skye Bioscience, Inc.'s common stock as of March 31, 2025.